

**Table S2. Technology Appraisals used in text analysis**

TA	STA / MTA	Published	Title
TA114	MTA	24-Jan-07	Methadone and buprenorphine for the management of opioid dependence
TA115	STA	24-Jan-07	Naltrexone for the management of opioid dependence
TA116	STA	24-Jan-07	Gemcitabine for the treatment of metastatic breast cancer
TA117	STA	24-Jan-07	Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
TA118	MTA	24-Jan-07	Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
TA119	STA	28-Feb-07	Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
TA121	STA	27-Jun-07	Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
TA123	STA	25-Jul-07	Varenicline for smoking cessation
TA124	STA	22-Aug-07	Pemetrexed for the treatment of non-small-cell lung cancer
TA127	STA	22-Aug-07	Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
TA128	MTA	26-Sep-07	Stapled haemorrhoidopexy for the treatment of haemorrhoids
TA129	STA	23-Oct-07	Bortezomib monotherapy for relapsed multiple myeloma
TA131	MTA	28-Nov-07	Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years
TA134	STA	23-Jan-08	Infliximab for the treatment of adults with psoriasis
TA135	MTA	23-Jan-08	Pemetrexed for the treatment of malignant pleural mesothelioma
TA136	STA	27-Feb-08	Structural neuroimaging in first-episode psychosis
TA137	STA	27-Feb-08	Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
TA138	MTA	26-Mar-08	Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
TA139	MTA	26-Mar-08	Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome
TA145	STA	25-Jun-08	Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
TA146	STA	25-Jun-08	Adalimumab for the treatment of adults with psoriasis
TA151	MTA	23-Jul-08	Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
TA152	MTA	23-Jul-08	Drug-eluting stents for the treatment of coronary artery disease
TA153	STA	27-Aug-08	Entecavir for the treatment of chronic hepatitis B
TA154	STA	27-Aug-08	Telbivudine for the treatment of chronic hepatitis B
TA155	MTA	27-Aug-08	Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
TA156	MTA	27-Aug-08	Routine antenatal anti-D prophylaxis for women who are rhesus D negative
TA157	STA	24-Sep-08	Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
TA158	MTA	24-Sep-08	Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
TA159	MTA	22-Oct-08	Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin
TA160	MTA	27-Oct-08	Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
TA161	MTA	27-Oct-08	Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
TA163	STA	17-Dec-08	Infliximab for acute exacerbations of ulcerative colitis
TA164	STA	17-Dec-08	Febuxostat for the management of hyperuricaemia in people with gout
TA165	MTA	28-Jan-09	Machine perfusion systems and cold static storage of kidneys from deceased donors
TA166	MTA	28-Jan-09	Cochlear implants for children and adults with severe to profound deafness
TA167	MTA	25-Feb-09	Endovascular stent–grafts for the treatment of abdominal aortic aneurysms
TA168	MTA	25-Feb-09	Amantadine, oseltamivir and zanamivir for the treatment of influenza
TA169	MTA	25-Mar-09	Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
TA170	STA	22-Apr-09	Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

TA171	STA	18-Jun-09	Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
TA172	STA	24-Jun-09	Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
TA173	STA	22-Jul-09	Tenofovir disoproxil for the treatment of chronic hepatitis B
TA174	STA	22-Jul-09	Rituximab for the first-line treatment of chronic lymphocytic leukaemia
TA177	STA	26-Aug-09	Alitretinoin for the treatment of severe chronic hand eczema
TA178	MTA	26-Aug-09	Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
TA179	STA	23-Sep-09	Sunitinib for the treatment of gastrointestinal stromal tumours
TA180	STA	23-Sep-09	Ustekinumab for the treatment of adults with moderate to severe psoriasis
TA181	STA	23-Sep-09	Pemetrexed for the first-line treatment of non-small-cell lung cancer
TA183	STA	28-Oct-09	Topotecan for the treatment of recurrent and stage IVB cervical cancer
TA184	MTA	25-Nov-09	Topotecan for the treatment of relapsed small-cell lung cancer
TA185	STA	24-Feb-10	Trabectedin for the treatment of advanced soft tissue sarcoma
TA187	MTA	19-May-10	Infliximab and adalimumab for the treatment of Crohn's disease
TA188	MTA	26-May-10	Human growth hormone (somatropin) for the treatment of growth failure in children
TA189	STA	26-May-10	Sorafenib for the treatment of advanced hepatocellular carcinoma
TA190	STA	23-Jun-10	Pemetrexed for the maintenance treatment of non-small-cell lung cancer
TA191	STA	28-Jul-10	Capecitabine for the treatment of advanced gastric cancer
TA192	STA	28-Jul-10	Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
TA193	STA	28-Jul-10	Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
TA195	MTA	25-Aug-10	Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
TA197	STA	25-Aug-10	Dronedarone for the treatment of non-permanent atrial fibrillation
TA199	MTA	25-Aug-10	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
TA200	MTA	22-Sep-10	Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
TA202	STA	27-Oct-10	Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
TA204	STA	27-Oct-10	Denosumab for the prevention of osteoporotic fractures in postmenopausal women
TA208	STA	24-Nov-10	Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
TA209	MTA	24-Nov-10	Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
TA210	MTA	15-Dec-10	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
TA211	STA	15-Dec-10	Prucalopride for the treatment of chronic constipation in women
TA212	STA	15-Dec-10	Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
TA213	STA	26-Jan-11	Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
TA214	STA	23-Feb-11	Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
TA215	STA	23-Feb-11	Pazopanib for the first-line treatment of advanced renal cell carcinoma
TA216	STA	23-Feb-11	Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
TA217	MTA	23-Mar-11	Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
TA218	STA	23-Mar-11	Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
TA220	STA	27-Apr-11	Golimumab for the treatment of psoriatic arthritis
TA221	STA	27-Apr-11	Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
TA223	MTA	25-May-11	Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
TA225	STA	22-Jun-11	Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
TA226	STA	22-Jun-11	Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
TA227	STA	29-Jun-11	Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
TA228	STA	27-Jul-11	Bortezomib and thalidomide for the first-line treatment of multiple myeloma
TA229	STA	27-Jul-11	Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion

TA230	STA	27-Jul-11	Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
TA232	STA	27-Jul-11	Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
TA235	STA	26-Oct-11	Mifamurtide for the treatment of osteosarcoma
TA236	STA	26-Oct-11	Ticagrelor for the treatment of acute coronary syndromes
TA238	STA	14-Dec-11	Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
TA239	STA	14-Dec-11	Fulvestrant for the treatment of locally advanced or metastatic breast cancer
TA242	MTA	25-Jan-12	Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy
TA243	MTA	25-Jan-12	Rituximab for the first-line treatment of stage III-IV follicular lymphoma
TA244	STA	25-Jan-12	Roflumilast for the management of severe chronic obstructive pulmonary disease
TA245	STA	25-Jan-12	Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
TA246	MTA	22-Feb-12	Pharmalgen for the treatment of bee and wasp venom allergy
TA247	STA	22-Feb-12	Tocilizumab for the treatment of rheumatoid arthritis
TA249	STA	15-Mar-12	Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
TA252	STA	25-Apr-12	Telaprevir for the treatment of genotype 1 chronic hepatitis C
TA253	STA	25-Apr-12	Boceprevir for the treatment of genotype 1 chronic hepatitis C
TA254	STA	25-Apr-12	Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
TA256	STA	23-May-12	Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
TA257	MTA	27-Jun-12	Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
TA258	STA	27-Jun-12	Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
TA259	STA	27-Jun-12	Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA260	STA	27-Jun-12	Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
TA261	STA	25-Jul-12	Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
TA263	STA	22-Aug-12	Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
TA264	STA	26-Sep-12	Alteplase for treating acute ischaemic stroke
TA265	MTA	24-Oct-12	Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
TA266	STA	28-Nov-12	Mannitol dry powder for inhalation for treating cystic fibrosis
TA267	STA	28-Nov-12	Ivabradine for treating chronic heart failure
TA268	STA	12-Dec-12	Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
TA269	STA	12-Dec-12	Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
TA272	STA	23-Jan-13	Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
TA274	STA	27-Feb-13	Ranibizumab for treating diabetic macular oedema
TA275	STA	27-Feb-13	Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
TA276	MTA	27-Mar-13	Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
TA278	MTA	24-Apr-13	Omalizumab for treating severe persistent allergic asthma
TA279	MTA	24-Apr-13	Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures
TA282	STA	24-Apr-13	Pirfenidone for treating idiopathic pulmonary fibrosis
TA283	STA	22-May-13	Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
TA284	STA	22-May-13	Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
TA285	STA	22-May-13	Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
TA287	STA	26-Jun-13	Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
TA288	STA	26-Jun-13	Dapagliflozin in combination therapy for treating type 2 diabetes
TA290	STA	26-Jun-13	Mirabegron for treating symptoms of overactive bladder
TA291	STA	26-Jun-13	Pegloticase for treating severe debilitating chronic tophaceous gout

TA292	STA	24-Jul-13	Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
TA293	STA	24-Jul-13	Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
TA294	STA	24-Jul-13	Aflibercept solution for injection for treating wet age-related macular degeneration
TA297	STA	23-Oct-13	Ocriplasmin for treating vitreomacular traction
TA298	STA	27-Nov-13	Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
TA300	MTA	27-Nov-13	Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
TA301	STA	27-Nov-13	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
TA303	STA	22-Jan-14	Teriflunomide for treating relapsing–remitting multiple sclerosis
TA304	MTA	26-Feb-14	Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip
TA305	STA	26-Feb-14	Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
TA306	STA	26-Feb-14	Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma
TA307	STA	25-Mar-14	Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
TA308	STA	26-Mar-14	Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
TA310	STA	23-Apr-14	Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
TA311	STA	23-Apr-14	Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
TA312	STA	28-May-14	Alemtuzumab for treating relapsing-remitting multiple sclerosis
TA314	MTA	25-Jun-14	Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure
TA315	STA	25-Jun-14	Canagliflozin in combination therapy for treating type 2 diabetes
TA316	STA	23-Jul-14	Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
TA317	MTA	23-Jul-14	Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
TA318	STA	23-Jul-14	Lubiprostone for treating chronic idiopathic constipation
TA319	STA	23-Jul-14	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
TA320	STA	27-Aug-14	Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
TA321	STA	22-Oct-14	Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
TA322	STA	24-Sep-14	Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
TA323	MTA	26-Nov-14	Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
TA324	MTA	26-Nov-14	Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
TA325	STA	26-Nov-14	Nalmefene for reducing alcohol consumption in people with alcohol dependence
TA326	STA	26-Nov-14	Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
TA327	STA	17-Dec-14	Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
TA329	MTA	25-Feb-15	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
TA330	STA	25-Feb-15	Sofosbuvir for treating chronic hepatitis C
TA331	STA	25-Feb-15	Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
TA333	STA	25-Feb-15	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
TA335	STA	25-Mar-15	Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
TA336	STA	25-Mar-15	Empagliflozin in combination therapy for treating type 2 diabetes
TA337	STA	25-Mar-15	Rifaximin for preventing episodes of overt hepatic encephalopathy
TA339	STA	08-Jun-15	Omalizumab for previously treated chronic spontaneous urticaria
TA340	STA	04-Jun-15	Ustekinumab for treating active psoriatic arthritis
TA341	STA	04-Jun-15	Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
TA342	STA	05-Jun-15	Vedolizumab for treating moderately to severely active ulcerative colitis
TA343	STA	02-Jun-15	Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
TA344	STA	02-Jun-15	Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

TA345	STA	22-Jul-15	Naloxegol for treating opioid-induced constipation
TA346	STA	22-Jul-15	Aflibercept for treating diabetic macular oedema
TA347	STA	22-Jul-15	Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
TA348	STA	22-Jul-15	Everolimus for preventing organ rejection in liver transplantation
TA349	STA	22-Jul-15	Dexamethasone intravitreal implant for treating diabetic macular oedema
TA350	STA	22-Jul-15	Secukinumab for treating moderate to severe plaque psoriasis
TA352	STA	26-Aug-15	Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
TA354	STA	26-Aug-15	Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
TA355	STA	23-Sep-15	Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
TA357	STA	07-Oct-15	Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
TA358	STA	28-Oct-15	Tolvaptan for treating autosomal dominant polycystic kidney disease
TA359	STA	28-Oct-15	Idelalisib for treating chronic lymphocytic leukaemia
TA360	STA	28-Oct-15	Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
TA363	STA	25-Nov-15	Ledipasvir–sofosbuvir for treating chronic hepatitis C
TA364	STA	25-Nov-15	Daclatasvir for treating chronic hepatitis C
TA365	STA	25-Nov-15	Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
TA366	STA	25-Nov-15	Pembrolizumab for advanced melanoma not previously treated with ipilimumab
TA367	STA	25-Nov-15	Vortioxetine for treating major depressive episodes
TA369	STA	16-Dec-15	Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
TA370	STA	16-Dec-15	Bortezomib for previously untreated mantle cell lymphoma
TA371	STA	16-Dec-15	Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
TA373	MTA	16-Dec-15	Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
TA374	MTA	16-Dec-15	Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
TA375	MTA	26-Jan-16	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
TA377	STA	27-Jan-16	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
TA378	STA	27-Jan-16	Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
TA379	STA	27-Jan-16	Nintedanib for treating idiopathic pulmonary fibrosis
TA380	STA	27-Jan-16	Panobinostat for treating multiple myeloma after at least 2 previous treatments
TA381	STA	27-Jan-16	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
TA383	STA	01-Feb-16	TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
TA384	STA	18-Feb-16	Nivolumab for treating advanced (unresectable or metastatic) melanoma
TA385	STA	24-Feb-16	Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
TA386	STA	23-Mar-16	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
TA387	STA	27-Apr-16	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
TA388	STA	27-Apr-16	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
TA389	MTA	27-Apr-16	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
TA390	MTA	25-May-16	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
TA391	STA	25-May-16	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
TA392	STA	22-Jun-16	Adalimumab for treating moderate to severe hidradenitis suppurativa
TA393	STA	22-Jun-16	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA394	STA	22-Jun-16	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
TA395	STA	22-Jun-16	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
TA396	STA	22-Jun-16	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma

TA397	STA	22-Jun-16	Belimumab for treating active autoantibody-positive systemic lupus erythematosus
TA398	STA	27-Jul-16	Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
TA399	STA	27-Jul-16	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
TA400	STA	27-Jul-16	Nivolumab in combination with ipilimumab for treating advanced melanoma
TA401	STA	24-Aug-16	Bosutinib for previously treated chronic myeloid leukaemia
TA402	STA	24-Aug-16	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
TA403	STA	24-Aug-16	Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
TA404	STA	24-Aug-16	Degarelix for treating advanced hormone-dependent prostate cancer
TA405	STA	24-Aug-16	Trifluridine–tipiracil for previously treated metastatic colorectal cancer
TA406	STA	28-Sep-16	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
TA407	STA	28-Sep-16	Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
TA408	STA	28-Sep-16	Pegaspargase for treating acute lymphoblastic leukaemia
TA409	STA	28-Sep-16	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
TA410	STA	28-Sep-16	Talimogene laherparepvec for treating unresectable metastatic melanoma
TA411	STA	28-Sep-16	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
TA412	STA	28-Sep-16	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
TA413	STA	26-Oct-16	Elbasvir–grazoprevir for treating chronic hepatitis C
TA414	STA	26-Oct-16	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
TA415	STA	26-Oct-16	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
TA416	STA	26-Oct-16	Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
TA417	STA	23-Nov-16	Nivolumab for previously treated advanced renal cell carcinoma
TA418	STA	23-Nov-16	Dapagliflozin in triple therapy for treating type 2 diabetes
TA419	STA	23-Nov-16	Apremilast for treating moderate to severe plaque psoriasis
TA420	STA	14-Dec-16	Ticagrelor for preventing atherothrombotic events after myocardial infarction
TA421	STA	21-Dec-16	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
TA422	STA	21-Dec-16	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
TA423	STA	21-Dec-16	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
TA424	STA	21-Dec-16	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
TA425	MTA	21-Dec-16	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
TA426	MTA	21-Dec-16	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia